



**Press Release**  
May 24, 2012  
Gothenburg, Sweden

## **Vitrolife named as winner of the 2012 SwedenBIO Award**

**Vitrolife has been named as the winner of the 2012 SwedenBIO Award. The prize is awarded by SwedenBIO, which is an association of member companies with the aim of promoting growth in the Life Science industry in Sweden. State Secretary Håkan Ekengren today awarded the distinction to Vitrolife at SwedenBIO's Annual Meeting.**

The jury's statement was as follows: "Through its innovative products and focus on the customer, Vitrolife has succeeded in building up a profitable and rapidly growing company that has attained international positions and international recognition. The winner has 37 quarters in a row of revenue growth as well as important and promising research. The jury particularly wishes to mention that Vitrolife has charted the world's previously unknown regulatory territory and left a clear map with regard to IVF."

The prize has been instituted to draw attention to prominent companies and leaders within the Life Science industry. This year's prize is the sixth to be awarded and previous winners are Aerocrine, BioInvent, Cellavision, Medivir and Gyros.

"We are extremely proud to have been awarded this distinction. We see the award as a result of our many years of work to contribute to life being created and prolonged. For us this prestigious prize means a strengthening of our standing, which we hope will lead to further successes," says Thomas Axelsson, CEO of Vitrolife.

May 24, 2012  
Gothenburg, Sweden  
VITROLIFE AB (publ)  
Thomas Axelsson  
CEO

### **For further information, please see the SwedenBIO website or contact:**

Thomas Axelsson, CEO, +46 31 721 80 01  
Mikael Engblom, CFO, phone +46 31 721 80 14

[Vitrolife](#) is a global biotechnology/medical device Group that works in the areas of Fertility and Transplantation. The [Fertility](#) product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes. The [Transplantation](#) product area works with solutions and systems for assessing and preserving organs outside the body, so as to be able to select usable organs and keep them in optimal condition pending transplantation.

[Vitrolife](#) today has approximately 220 employees and the company's products are sold in almost 90 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China and Japan. The [Vitrolife share](#) is listed on [NASDAQ OMX Stockholm](#), Small Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 99.  
E-mail: [info@vitrolife.com](mailto:info@vitrolife.com). Website: [www.vitrolife.com](http://www.vitrolife.com).

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on May 24, 2012 at 17:30 p.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.